

Roche in Switzerland

2009 edition

A leader worldwide and at home

Roche was founded in Basel in 1896. Although the company began establishing operations abroad in the same year and today employs 80,000 people in around 150 countries, Switzerland is still home to the Group's headquarters and remains an important operational centre.

The Roche companies operating in Northwestern and Central Switzerland and in the cantons of Berne and Zurich play a key role in the global research and production network. Roche medicines and Roche diagnostic systems from Switzerland are supplied to patients, physicians, hospitals, pharmacies and laboratories throughout the world.

Roche is one of the largest Swiss companies on the stock market in terms of market capitalisation. The great majority of people who own shares of Roche Holding Ltd, listed on the SWX Swiss Exchange, are residents of Switzerland. At the same time, just over half of the voting shares are held by the descendants of the company's founders; as a result, the stability and strength of the ownership structure are almost unrivalled anywhere in the world.

Contents

- A major employer
 - A leader in research, development and production
 - Roche sites in Switzerland ... and partner sites ... and their businesses
 - A successful player in the Swiss pharmaceuticals and diagnostics markets
 - A tradition of commitment
-

A major employer


Did you know that...?

- In 2008, Roche paid a total of over 1.5 billion Swiss francs in wages and salaries in Switzerland.
- With around 350 apprentices in 17 occupational fields and more than 100 special entry-level positions for young academics, Roche is one of the country's biggest providers of education and training.
- Almost 40 years ago, Roche was one of the first major companies in Switzerland to introduce an employee profit-sharing plan. Since then, all Roche employees in Switzerland have accrued the same benefits under the plan to supplement their occupational pension benefits.
- Roche's Swiss companies employ people from around 70 different countries; women account for some 40% of the workforce.
- Roche is one of the four largest private-sector employers in the canton of Zug and in the region of Northwestern Switzerland.
- Over the last few years, Roche has created more than 500 new jobs in Rotkreuz.

In 2008, Roche employed around 10,000 people in Switzerland – over 12% of Roche's total workforce worldwide. In the past years, Roche has created more than 1,400 new jobs in Switzerland. In contrast to other companies,

Roche has an in-house infrastructure for training apprentices. This allows it to respond very rapidly to the company's needs. Biotechnology, for example, was integrated into Roche's training programme in record time.

Number of Roche employees in Switzerland



Continuing businesses / Source: Roche

Switzerland's top ten private-sector employers

Company	Number of staff
1. Migros	61,000
2. Coop	40,000
3. Swiss Post	38,000
4. Swiss Federal Railways	27,800
5. UBS	27,000
6. Credit Suisse	21,500
7. Swisscom	16,000
8. Novartis	12,500
9. Roche Group	9,991
10. Nestlé	8,650

Totals rounded / Source: Sonntag

Roche staff qualifications




Roche in Northwestern Switzerland / Source: Roche

A leader in research, development and production

Switzerland accounts for about a fifth of Roche's total R&D investment of almost 9 billion Swiss francs worldwide. More than 3,000 R&D staff are

employed at Roche Basel alone. This makes Roche one of the three leading research organisations in the healthcare sector in Switzerland.

Roche's R&D investment



Continuing businesses, CHF million; annual data not always directly comparable / Source: Roche

New CHF 200 million building in Kaiseraugst

The primary function of the new, state-of-the-art galenical production facility will be to formulate biotech active ingredients into medicines for injection or infusion. Roche has expanded its production capacity to ensure that it can continue to meet the constantly growing demand for medicines such as Avastin, Herceptin and MabThera for the treatment of cancer or Pegasys for hepatitis. At the Kaiseraugst facility, high-speed technologies will make it possible to produce up to 400 ampoules and up to 300 prefilled syringes a minute. The building

comprises three above-ground storeys and a basement. Qualification of the new facility will continue until 2010 and be followed by official certification. Delivery of the first drugs to be manufactured here is scheduled for 2010.



Did you know that...?

- Roche accounts for one in every 11 Swiss francs spent on R&D in this country.
- Roche is the country's largest manufacturer of fully auto-mated in-vitro diagnostic systems – over the last 40 years, more than 65,000 instruments have been produced at Rotkreuz.
- Roche is committed to the ambitious goal of reducing energy consumption per employee by 10% by 2010 (from 2005 levels).
- Roche exports generate a flow of 17,000 Swiss francs every minute – or 1 million Swiss francs an hour – into Switzerland.
- Roche's purchases of goods and services from Swiss companies – including many SMEs – total roughly one-half to a full billion Swiss francs each year.
- In Development alone, around 1,000 people work at Roche Basel, with roughly another 500 at Roche Diagnostics Rotkreuz.
- In Switzerland, many laboratory tests are performed at the physician's office. For the majority of these tests, Roche products are used: thanks to continuous innovation in cardiovascular markers and coagulation monitoring, Roche has become the market leader in the primary care setting.

Roche sites in Switzerland...

Company	Site	No. of employees	
F. Hoffmann-La Roche Ltd ■	Basel (Canton Basel-Stadt), Kaiseraugst (Canton Aargau)	7,775	The headquarters of the Roche Group
Roche Pharma (Switzerland) Ltd. ■	Reinach (Canton Basel-Landschaft)	153	The Swiss pharmaceuticals business
Roche Diagnostics (Schweiz) Ltd. ■	Rotkreuz (Canton Zug)	152	The Swiss diagnostics business
Roche Diagnostics Ltd. ■	Rotkreuz (Canton Zug)	1,248	One of the main sites of the global Diagnostics Division
Disetronic Medical Systems Ltd. ■	Burgdorf (Canton Berne)	328	Roche Diabetes Care's centre of expertise for insulin delivery systems
GlycArt Biotechnology AG ■	Schlieren (Canton Zurich)	56	A biotechnology research site
Others*		279	
Roche Switzerland		9,991	

* Roche Diagnostics International Ltd (international controlling for diagnostics products), Roche Forum Buonas AG (training and conference centre), Taverio AG (catering) and other companies - All figures given are for 2008 / Source: Roche

... and their businesses

In 1896, Fritz Hoffmann-La Roche founded the company on Grenzacherstrasse in Basel – since then, Roche has developed into a world leader in the healthcare industry. Headquarters is now one of Roche's largest centres for research, development, production and administrative functions.

Basel is home to the Corporate Executive Committee and Group functions, as well as the Pharmaceuticals and Diagnostics Divisions. The Pharmaceuticals Division's global functions are also located in Basel, as are parts of the division's worldwide research and production organisations. The

facilities at the nearby Kaiseraugst location – also considered to be part of the Basel site – include an international packaging and logistics centre. This supplies around 120 million packs of medicine to some 150 markets every year.

The Roche company in Reinach is primarily active in marketing and distribution of medicines and clinical research. In a variety of therapeutic areas, Roche seeks to

deliver integrated solutions, encompassing not only prevention, diagnosis and treatment, but also patient care. Key products include the cancer treatments Avastin,

Herceptin and MabThera (also effective in the treatment of rheumatoid arthritis), Recormon (anemia), Bonviva (osteoporosis) and Actemra (rheumatoid arthritis).

Roche Diagnostics (Schweiz) Ltd. is responsible for marketing, sales and service of diagnostic instruments, reagents and test strips. In the Swiss market, it serves patients, private and hospital laboratories, universities,

office-based physicians and research institutes. Its products are marketed under brand names such as Accu-Chek (monitoring systems for people with diabetes) and cobas (laboratory diagnostic products for clinical

chemistry, immunology and molecular diagnostics). The product range also includes reagents and instruments for public and private-sector life science research facilities.

Rotkreuz is the site of the headquarters of the Roche Professional Diagnostics business area, which supplies analytical systems and workflow solutions for laboratories, hospitals and physicians. The headquarters of Roche Diagnostics EMEA (Europe, Middle East, Africa)/LATAM (Latin

America) is also located at Rotkreuz. Roche Diagnostics Ltd. is one of the world's leading development, production and service centres for instrumentation and software systems used in diagnostics and bio-analytical research. It serves as Roche Diagnostics' centre of expertise for modern

equipment design and other key issues. Since 2007 it has also been one of the two global centres for the development of molecular diagnostic reagents and test systems, and for the production of test kits.

Since 2003 Disetronic has been part of Roche Diabetes Care (a business unit within the Roche Diagnostics Division).

Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for comprehensive diabetes management systems and services. The Burgdorf site is responsible

for the development and production of infusion systems (insulin pumps, infusion sets and accessories), the configuration of glucose monitoring systems and international marketing support.

Roche acquired the young biotechnology company GlycArt in the summer of 2005. GlycArt developed a unique technology designed to enhance the efficacy of antibody

therapeutics. GlycArt focuses on product development – from scientific concepts and validation to the corresponding studies. The compounds studied and developed by

GlycArt are boosting Roche's significant commitment to offering improved cancer medicines.



Roche headquarters, Basel (Canton Basel-Stadt)



Roche, Kaiseraugst (Canton Aargau)



Roche Pharma (Switzerland) Ltd., Reinach
(Canton Basel-Landschaft)



Roche Diagnostics, Rotkreuz (Canton Zug)




Roche - Disetronic Medical Systems Ltd., Burgdorf
(Canton Berne)



GlycArt Biotechnology AG, Schlieren (Canton Zurich)

... and partner sites



Roche sites

- 1 Basel / Kaiseraugst, F. Hoffmann-La Roche Ltd
- 2 Reinach, Roche Pharma (Switzerland) Ltd.
- 3 Rotkreuz, Roche Diagnostics (Schweiz) Ltd.
- 4 Rotkreuz, Roche Diagnostics Ltd.
- 5 Burgdorf, Disetronic Medical Systems Ltd.
- 6 Schlieren, GlycArt Biotechnology AG

Roche's main research partners

- 1 ▲ CSEM Alpnach, Zurich, Neuchâtel
- 2 ▲ Swiss Federal Institute of Technology, Zurich (ETH)
- 3 ▲ Swiss Federal Institute of Technology, Lausanne (EPFL)
- 4 ▲ University of Applied Sciences Northwestern Switzerland, Muttenz
- 5 ▲ University of Applied Sciences Wädenswil
- 6 ▲ Paul Scherrer Institut, Villigen
- 7 ▲ Swiss Institute for Experimental Cancer Research, Epalinges
- 8 ▲ University of Basel (Biozentrum / Centre of Pharmaceutical Sciences)
- 9 ▲ University of Berne
- 10 ▲ University of Geneva
- 11 ▲ University of St. Gallen
- 12 ▲ University of Zurich
- 13 ▲ Zurich University of Applied Sciences, Winterthur
- 14 ▲ University Hospital Lausanne (CHUV)
- 15 ▲ Inselspital Bern, Berne
- 16 ▲ University Hospital Basel
- 17 ▲ Cantonal Hospital St. Gallen
- 18 ▲ Actelion, Allschwil
- 19 ▲ Basilea, Basel
- 20 ▲ Helsinn Healthcare, Pazallo

Roche employees by place of residence

- 1,000–2,500 employees
- 500–1,000 employees
- 100–500 employees
- 10–100 employees
- 0–10 employees

A successful player in the Swiss pharmaceuticals and diagnostics markets


Did you know that...?

- In view of the genuine added value that Roche's innovative medicines offer patients, the Swiss regulatory authorities often review Roche submissions under a fast-track procedure. There were eight such reviews in the last three years. Additional indications were approved for MabThera and Avastin in fast-track reviews this year – and more are to follow.
- Every day, some 150,000 people with diabetes in Switzerland use Roche products, leading to greater independence and lower medical costs. Four out of five people using insulin pumps to treat diabetes choose a Roche product.
- The tax revenues generated by Roche – the company, employees, shareholders and suppliers – outstrip Roche's sales in Switzerland.
- The cancer treatment Avastin won this year's Walter Siegenthaler Award, which recognises innovative pharmaceutical developments. With its precise mode of action, Avastin helps to control tumour growth and metastases.

Roche concentrates exclusively on innovative medicines and diagnostic approaches that offer decisive advantages over existing products and solutions. This clear focus has also proved successful in Switzerland:

Roche is no. 1 in the hospital market, in cancer therapy and in all areas of *in-vitro* diagnostics, of which blood screening and diabetes care are two examples.

Roche's sales in Switzerland



Continuing businesses, CHF million / Source: Roche

New high-rise accommodating some 620 workplaces at Rotkreuz

As part of the site development programme at Rotkreuz, Roche is constructing the fifth new building in as many years. In November 2009, the foundation stone is to be laid for the new 68 metre high-rise, which is to bring together all the administrative and site service functions under one roof. The 16-storey building will accommodate some 620 workplaces on a gross floor area

measuring 17,236 square metres. The building will be enclosed in a transparent, highly energy-efficient all-glass facade. Construction is scheduled to be completed by May 2011. The planned investment of around 90 million Swiss francs is a further expression of Roche's commitment to the Rotkreuz site.



A tradition of commitment

For Roche, supporting scientific, social, humanitarian and cultural projects – in Switzerland and abroad – is an integral part of its role as a corporate citizen. In

addition, the company has traditionally played a major part in promoting green technologies and minimising adverse impacts on the environment.

“Cycle for Life”: dedication and stamina



“Cycle for Life” is an annual fund-raising event organised by employees at the Roche

site in Reinach. In September 2009 participating employees and members of the healthcare community rode once round the entire country to raise cancer awareness and collect money for Swiss patient organisations. “Cycle for Life” demonstrates that, as well as seeking to develop differentiated medicines for illnesses that cannot yet be properly treated, Roche employees are committed to helping patients in their spare time too. Roche management in Reinach is supporting this initiative and rounds up the sum raised.

Protecting nature and the environment in Buonas, Canton Zug



Roche and Canton Zug are engaged in a joint reed protection project in Buonas: reed beds have been planted on the Buonas peninsula on the shore of Lake Zug. The reeds native to this wetland area are a valuable component of the ecosystem, and the reed beds can now be further expanded. Roche has set itself the goal of honouring and preserving Buonas' cultural and scenic heritage, and it is therefore pleased to be able to support the Canton Zug Reed Protection Working Group.

Did you know that...?

- Roche makes a substantial contribution to the promotion of scientific research, e.g. through the global Roche Postdoc Fellowship programme and by supporting the “Schweizer Jugend forscht” foundation for young researchers.
- At the University of Basel, a Roche Chair of Immunology has been endowed with 12 million Swiss francs for a period of at least 25 years. Roche has also established numerous research collaborations with Swiss universities, in areas including systems biology.
- Roche founded – and continues to fund – the Museum Tinguely as a gift to the city of Basel. Roche'n'Jazz concerts are held at the museum every month, in partnership with the Basel bird's eye jazz club. The company thus contributes significantly to the city's rich cultural life.
- Employees at Roche Diagnostics Rotkreuz receive a green bonus for environment-friendly commuting.
- Roche promotes work-life balance, e.g. by offering flexible working arrangements and providing a total of 175 childcare places.
- Kitchen and food waste from the staff canteen in Rotkreuz is used to generate up to 50,000 kilowatt-hours of energy per year in the form of biogas.

Impressum

F. Hoffmann-La Roche Ltd
Corporate Communications
CH-4070 Basel

Tel. +41 (0)61 688 11 11
E-mail:
basel.webmaster@roche.com

“Roche in Switzerland” is
also available in French,
German and Italian.

© 2009

All trademarks used
or mentioned are
legally protected.

7 000 731-4

Roche in Switzerland

With R&D expenditure of almost 1.9 billion Swiss francs and investments of more than 420 million Swiss francs per year, Roche in Switzerland plays a key role in the Group's global research, development and production network. At Group headquarters in Basel and at other sites in Northwestern and Central Switzerland and in the cantons of Berne and Zurich, Roche employs a total of some 10,000 people. As a leader in the pharmaceuticals and *in-vitro* diagnostics sectors, Roche posted sales of 509 million Swiss francs in Switzerland in 2008.

www.roche.ch

Roche Group

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in *in-vitro* diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims to provide medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.

www.roche.com